Results of a Large-Scale Study of the Binding of 50 Type II Inhibitors to 348 Kinases: The Role of Protein Reorganization

一项大规模研究50种II型抑制剂与348种激酶结合的结果:蛋白质重组的作用

阅读:2

Abstract

Protein kinases constitute the second largest class of drug targets, most prominently in cancer therapy. In this work, we focus on type II kinase inhibitors that bind to the "classical" inactive conformation. We analyze binding affinities of 50 type II inhibitors across 348 kinases, combining earlier results for 16 inhibitors (the "Davis data set") with recently obtained measurements for the remaining 34 (the "Schrödinger data set"). Using a Potts statistical energy model, we investigate the role of protein conformational reorganization in kinase selectivity and find that protein reorganization makes a large contribution to the selectivity (ROC AUC ∼0.8). We compare Potts threading predictions for the binding of 50 type II inhibitors to 348 kinases with those of DeepDTAGen, a sequence-based model trained on the Davis data set containing both type I and type II kinase inhibitors. DeepDTAGen performs well for the 16 inhibitors in the Davis data set but poorly for the remaining 34 in the Schrödinger data set, representing unseen data.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。